Key Points
- Amylyx Pharmaceuticals director George Milne Jr. sold 30,000 shares at an average price of $27.70, generating $831,000. His remaining 782,881-share stake is valued at approximately $21.7 million.
- AMLX shares opened at $27.43 and were down 2.2%, while the company recently reported a quarterly loss of $0.39 per share, missing estimates by $0.03.
- Analyst sentiment remains positive, with an average “Buy” rating and a consensus price target of $38.86; institutional investors own 95.84% of the company.
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) Director George Milne, Jr. sold 30,000 shares of the stock in a transaction that occurred on Monday, October 5th. The stock was sold at an average price of $27.70, for a total transaction of $831,000.00. Following the transaction, the director owned 782,881 shares in the company, valued at approximately $21,685,803.70. The trade was a 3.69% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Amylyx Pharmaceuticals Trading Down 2.2%
Shares of AMLX opened at $27.43 on Thursday. Amylyx Pharmaceuticals, Inc. has a 12 month low of $10.83 and a 12 month high of $41.14. The firm's 50 day moving average is $30.13 and its 200-day moving average is $20.89. The stock has a market capitalization of $3.06 billion, a PE ratio of -19.18 and a beta of -0.10.
Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.03). Equities research analysts predict that Amylyx Pharmaceuticals, Inc. will post -1.48 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Amylyx Pharmaceuticals
A number of large investors have recently modified their holdings of the business. Integrated Wealth Concepts LLC bought a new position in shares of Amylyx Pharmaceuticals in the 2nd quarter valued at $157,000. Arizona State Retirement System lifted its position in shares of Amylyx Pharmaceuticals by 9.5% during the 2nd quarter. Arizona State Retirement System now owns 19,825 shares of the company's stock worth $356,000 after buying an additional 1,726 shares during the last quarter. Corient Private Wealth LP bought a new stake in shares of Amylyx Pharmaceuticals during the 2nd quarter worth $1,065,000. Alyeska Investment Group L.P. acquired a new stake in Amylyx Pharmaceuticals in the second quarter valued at about $18,912,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Amylyx Pharmaceuticals by 10.4% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 173,407 shares of the company's stock valued at $3,114,000 after buying an additional 16,318 shares in the last quarter. Institutional investors and hedge funds own 95.84% of the company's stock.
Wall Street Analysts Forecast Growth
AMLX has been the subject of a number of recent analyst reports. Citigroup upped their target price on Amylyx Pharmaceuticals from $20.00 to $26.00 and gave the company a "buy" rating in a research report on Monday, August 3rd. Wolfe Research upgraded Amylyx Pharmaceuticals to a "strong-buy" rating in a research report on Monday, August 17th. Robert W. Baird boosted their price target on Amylyx Pharmaceuticals from $28.00 to $52.00 and gave the company an "outperform" rating in a research note on Wednesday, August 19th. Mizuho upped their price objective on shares of Amylyx Pharmaceuticals from $30.00 to $42.00 and gave the stock an "outperform" rating in a research report on Tuesday, August 18th. Finally, HC Wainwright upped their price objective on shares of Amylyx Pharmaceuticals from $34.00 to $55.00 and gave the stock a "buy" rating in a research report on Tuesday, August 18th. Two analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Amylyx Pharmaceuticals has an average rating of "Buy" and an average price target of $38.86.
View Our Latest Analysis on AMLX
Amylyx Pharmaceuticals Company Profile
(
Get Free Report)
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
